Five years ago, it would have been “unheard of” for a private equity fund to maintain a substantial minority shareholder position following the sale of one of its portfolio companies, say the leaders of McDermott Will & Emery’s corporate practice.

But that’s exactly what happened this year when Boston-based client Ampersand Capital Partners rolled over its entire equity stake in biotech provider Vivitide, when KKR-backed Biosynth Carbosyn acquired the company. Lawyers at the firm say Ampersand maintains a “substantial” minority stake in the combined entity, which introduces novel issues related to governance structures and the seller’s ability to retrieve its investment by a certain date.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]